At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
OZEM Roundhill GLP-1 & Weight Loss ETF
Trading 09-19 12:56:28 EDT
28.55
+0.40
+1.42%
High
28.74
Low
28.50
Vol
18.04K
Open
28.70
D1 Closing
28.15
Amplitude
0.85%
Mkt Cap
47.11M
Tradable Cap
47.11M
Total Shares
1.65M
T/O
516.57K
T/O Rate
1.09%
Tradable Shares
1.65M
P/B
--
ROE
--
EPS
0.00
52wk High
--
52wk Low
--
P/E
--
Dividend
--
Div.Yield
--
ROA
--
Time
5D
D
W
M
News
New Post(s)
Profile
Tap the Weight-Loss Drug Market With These ETFs
Zacks · 09-18 23:00
Tap the Weight-Loss Drug Market With These ETFs
Stock Market Turns The Heat Up On Speculators
Blockhead · 09-06
Stock Market Turns The Heat Up On Speculators
5 ETFs to Make the Most of Eli Lilly's Strength
Zacks · 08-12
5 ETFs to Make the Most of Eli Lilly's Strength
ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment
Zacks · 07-23
ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment
HRTS: Exposure To GLP-1 Drug Developers Means Plenty Of Upside
seekingalpha · 07-19
HRTS: Exposure To GLP-1 Drug Developers Means Plenty Of Upside
Best ETF Areas of Last Week
Zacks · 06-12
Best ETF Areas of Last Week
ETFs to Profit from the Weight Loss Drug Boom
Zacks · 06-04
ETFs to Profit from the Weight Loss Drug Boom
Eli Lilly: Addressing Supply Challenges Should Accelerate Growth
seekingalpha · 05-27
Eli Lilly: Addressing Supply Challenges Should Accelerate Growth
Play These New ETFs to Tap Lucrative Weight Loss Drug Market
Zacks · 05-22
Play These New ETFs to Tap Lucrative Weight Loss Drug Market
Two US asset managers launch weight-loss ETFs
Reuters · 05-22
Two US asset managers launch weight-loss ETFs
Load more
Introduction
Company Name.
Roundhill GLP-1 & Weight Loss ETF
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--
{"stockData":{"symbol":"OZEM","market":"US","secType":"STK","nameCN":"Roundhill GLP-1 & Weight Loss ETF","latestPrice":28.55,"timestamp":1726764977928,"preClose":28.15,"halted":0,"volume":18038,"delay":0,"floatShares":1650000,"shares":1650000,"eps":0,"marketStatus":"Trading","change":0.4,"latestTime":"09-19 12:56:28 EDT","open":28.7,"high":28.74,"low":28.5,"amount":516569.646528,"amplitude":0.008526,"askPrice":28.75,"askSize":3000,"bidPrice":28.53,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1726776000000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":28.15,"sharesOutstanding":1650000,"nav":28.22,"aum":46563000,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":28.955,"preClose":28.15,"latestTime":"08:37 EDT","volume":10,"amount":289.54999999999995,"timestamp":1726749460608},"postHourTrading":{"tag":"盘后","latestPrice":28.5,"preClose":28.15,"latestTime":"19:35 EDT","volume":1001,"amount":28529,"timestamp":1726702525665},"volumeRatio":1.224822,"impliedVol":0.2408,"impliedVolPercentile":0.6234},"requestUrl":"/m/hq/s/OZEM","defaultTab":"news","newsList":[{"id":"2468531787","title":"Tap the Weight-Loss Drug Market With These ETFs","url":"https://stock-news.laohu8.com/highlight/detail?id=2468531787","media":"Zacks","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468531787?lang=en_us&edition=fundamental","pubTime":"2024-09-18 23:00","pubTimestamp":1726671600,"startTime":"0","endTime":"0","summary":"The weight-loss drug market is heating up with the introduction of GLP-1 pills. Novo Nordisk’s NVO Wegovy and Eli Lilly’s LLY Zepbound have been dominating this market and several other companies are also vying for a slice of the lucrative business. The latest data from Roche Holdings RHHBY, Novo Nordisk and smaller biotech proved that an oral option could be as effective as injectables.The new drugs in the pipeline are getting approval with potential for improvements such as less frequent administration by pill rather than by injection and fewer side effects .Investors seeking to tap the boom in weight-loss drug treatments could consider Roundhill GLP-1 & Weight Loss ETF OZEM, Amplify Weight Loss Drug & Treatment ETF THNR and GLP-1, Obesity & Cardiometabolic ETF HRTS.Roundhill GLP-1 & Weight Loss ETF Roundhill GLP-1 & Weight Loss ETF is the world’s first GLP-1 ETF and is actively managed. Roundhill believes that weight loss drugs, inclu","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/1H9NqoSNLfLtMd2fyMlfBA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/1H9NqoSNLfLtMd2fyMlfBA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tap-weight-loss-drug-market-150000819.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1093756325.SGD","LU0354030511.USD","LU0466842654.USD","LU0943347566.SGD","LU1280957306.USD","LU1064131342.USD","BK4533","LU0471298694.HKD","LU0385154629.USD","FDN","LLY","GB00BDT5M118.USD","BK4550","LU0823416689.USD","BK4516","LU1035775433.USD","BK4588","IE00BJLML261.HKD","LU0882574139.USD","RHHBY","NVO","IE0004445239.USD","THNR","IE00BFTCPJ56.SGD","LU0640476718.USD","HRTS","LU0820561909.HKD","03165","LU0096364046.USD","LU1061106388.HKD","OZEM","LU0079474960.USD","LU0097036916.USD","IE00BKVL7J92.USD","LU0882574055.USD","IE00BJJMRZ35.SGD","LU0058720904.USD","LU1551013342.USD","IE0002141913.USD","IE0009355771.USD","LU1069344957.HKD","LU0689472784.USD","LU0820561818.USD","LU0256863811.USD","LU0122379950.USD","LU0198837287.USD","BK4585","LU0354030438.USD","BK4007","LU0114720955.EUR"],"gpt_icon":1},{"id":"2465187156","title":"Stock Market Turns The Heat Up On Speculators","url":"https://stock-news.laohu8.com/highlight/detail?id=2465187156","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2465187156?lang=en_us&edition=fundamental","pubTime":"2024-09-06 19:00","pubTimestamp":1725620457,"startTime":"0","endTime":"0","summary":"Fund investors felt some heat in the stock market in August. And more could be coming in the traditionally tough September.","market":"fut","thumbnail":"https://www.investors.com/wp-content/uploads/2022/07/Stock-watchingstocks-01-adobe-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2022/07/Stock-watchingstocks-01-adobe-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.investors.com/etfs-and-funds/personal-finance/stock-market-turns-the-heat-up-on-speculators/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["OZEM","ICF","L","US6M.BOND","US3Y.BOND","REZ","LU0048584097.USD","US30Y.BOND","EFA","SPXU","US2Y.BOND","ESmain","OEX","US10Y.BOND","BK4534","IE00BFSS8Q28.SGD","SDS","SPY","IE00B19Z8X17.USD","VOO","US912797HE00.BOND","US912797GW17.BOND","3NVD.UK","BK4588","IVV","AGG","FDN","PPH.AU","NVDA","US12M.BOND",".SPX","IE00B3M56506.USD","US5Y.BOND","SSO","VUG","BK4527","REZ.AU","MBS","BK4579","OEF","US912797GL51.BOND","IE00B19Z8W00.USD","SH","VTV","UPRO","BK4141","PPH","2NVD.UK","IHI","US7Y.BOND"],"gpt_icon":1},{"id":"2459934200","title":"5 ETFs to Make the Most of Eli Lilly's Strength","url":"https://stock-news.laohu8.com/highlight/detail?id=2459934200","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459934200?lang=en_us&edition=fundamental","pubTime":"2024-08-12 23:50","pubTimestamp":1723477800,"startTime":"0","endTime":"0","summary":"Eli Lilly and Company LLY impressed investors with its robust second-quarter 2024 results on Aug 8. Shares jumped 9.5% following the earnings release and an additional 5.5% the next day.The pharmaceutical giant beat on both the top and bottom lines and raised its outlook for 2024, fueled by the strong demand for its diabetes and weight-loss products — Mounjaro and Zepbound. Impressed by blowout earnings, several analysts raised their target price on the stock .Investors seeking to tap the opportune moment could bet on ETFs having the largest exposure to the drugmaker. These include iShares U.S. Pharmaceuticals ETF IHE, Roundhill GLP-1 & Weight Loss ETF OZEM, Horizon Kinetics Medical ETF MEDX, Amplify Weight Loss Drug & Treatment ETF THNR and iShares U.S. Healthcare ETF IYH.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/qi8AmKRuXk4zL7mGsiR5yg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/qi8AmKRuXk4zL7mGsiR5yg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/5-etfs-most-eli-lillys-155000950.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B1BXHZ80.USD","BK4585","LU1061106388.HKD","LU0820561909.HKD","LU0882574055.USD","BK4550","IE00BK4W5L77.USD","LU0058720904.USD","LU0256863902.USD","LU0466842654.USD","IE00BJT1NW94.SGD","LU1023059063.AUD","BK4534","BK4588","LU0109391861.USD","FDN","LU0471298694.HKD","LU1551013425.SGD","IYH","LU0417517546.SGD","IE00BJJMRZ35.SGD","LU0096364046.USD","LU0097036916.USD","LU0385154629.USD","LU0708995401.HKD","LU0820561818.USD","LU1551013342.USD","LU0122379950.USD","MEDX","IE00BK4W5M84.HKD","LU0640476718.USD","BK4581","LU0672654240.SGD","OZEM","IE0002141913.USD","THNR","LLY","LU0320765059.SGD","LU0106261372.USD","LU0006306889.USD","LU0094547139.USD","LU0456855351.SGD","IE0004445239.USD","IE00B4R5TH58.HKD","LU0238689110.USD","IE0009355771.USD","LU1064131342.USD","IHE","IE00BJLML261.HKD","BK4516"],"gpt_icon":1},{"id":"2453124087","title":"ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment","url":"https://stock-news.laohu8.com/highlight/detail?id=2453124087","media":"Zacks","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2453124087?lang=en_us&edition=fundamental","pubTime":"2024-07-23 02:09","pubTimestamp":1721671740,"startTime":"0","endTime":"0","summary":"Global obesity rates have nearly tripled since 1975 and are expected to affect over half the population by 2035, per WHO and Goldman Sachs. Pioneering GLP-1 treatments, such as Ozempic, Wegovy, and Zepbound, are now at the forefront of medical advancements in weight management.GLP-1 medications, initially used to treat diabetes, were later discovered to suppress appetite and lead to considerable weight loss. Recent studies suggest that GLP-1 drugs may also slow the progression of Parkinson’s symptoms in humans and lower the risk of heart attack, stroke and cardiovascular death by approximately 20%.Shares of those companies slid due to rising competition. Roche recently announced encouraging Phase I trial data for its new obesity drug candidate, CT-996, acquired through Carmot Therapeutics. The once-daily pill showed a placebo-adjusted average weight loss of 6.1% in obese patients without Type 2 diabetes within four weeks. Roche's chief medical officer, Levi Garraway, emphasized the pot","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/g.raN2f2Gj9gsgHh3Sjz.Q--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/g.raN2f2Gj9gsgHh3Sjz.Q--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/etfs-focus-competition-heats-weight-180900279.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LLY","LU0471298777.SGD","BK4550","BK4533","BK4516","LU1804176565.USD","IE00BFTCPJ56.SGD","LU0097036916.USD","FDN","LU0256863902.USD","LU0943347566.SGD","LU0096364046.USD","LU0689472784.USD","IE0002141913.USD","LU0672654240.SGD","IE00B2B36J28.USD","LU1551013342.USD","BK4007","LU1093756325.SGD","LU1712237335.SGD","IE0009355771.USD","IE00BKVL7J92.USD","BK4534","IE00B4R5TH58.HKD","THNR","LU1069344957.HKD","LU0385154629.USD","LU0417517546.SGD","BK4585","LU0820561818.USD","LU0466842654.USD","LU0079474960.USD","LU0320765059.SGD","LU0640476718.USD","LU1267930730.SGD","LU0456855351.SGD","LU1623119135.USD","LU0238689110.USD","LU0820561909.HKD","HRTS","LU0114720955.EUR","LU1064131342.USD","OZEM","LU1061106388.HKD","LU0154236417.USD","LU0823416689.USD","LU0198837287.USD","LU0882574139.USD","GB00BDT5M118.USD","NVO"],"gpt_icon":1},{"id":"2452777654","title":"HRTS: Exposure To GLP-1 Drug Developers Means Plenty Of Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2452777654","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2452777654?lang=en_us&edition=fundamental","pubTime":"2024-07-19 22:59","pubTimestamp":1721401182,"startTime":"0","endTime":"0","summary":"By 2030, the weight loss drug market is estimated to reach a significant size, attracting many competitors due to the high prevalence of obesity-related comorbidities.The Tema Obesity & Cardiometaboli","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/487041745/image_487041745.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/487041745/image_487041745.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4705109-hrts-exposure-to-glp-1-drug-developers-means-plenty-of-upside","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["OZEM","LU1023059063.AUD","VKTX","BK4007","NQmain","GPCR","BK4139","MNQmain","PFE","TQQQ","IE00BK4W5M84.HKD","LLY","LU1894683264.USD","LU1093756325.SGD","LU0471298777.SGD","LU0289739699.SGD","NVO","IE00BBT3K403.USD","LU0943347566.SGD","LU0689472784.USD","IE00B2B36J28.USD","QID","SQQQ","BK4533","LU0882574139.USD","BK4532",".IXIC","LU0234572021.USD","IE00BLSP4239.USD","LU0471298694.HKD","QLD","LU0058720904.USD","LU0238689110.USD","LU0640476718.USD","LU0456855351.SGD","LU0094547139.USD","LU1551013342.USD","SG9999013999.USD","FDN","LU0868494617.USD","GLP","CDC","LU0079474960.USD","MDGL","HRTS","LU0256863902.USD","PSQ","BK4568","QQQ","IE00B1BXHZ80.USD"],"gpt_icon":1},{"id":"2442348458","title":"Best ETF Areas of Last Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2442348458","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2442348458?lang=en_us&edition=fundamental","pubTime":"2024-06-12 01:00","pubTimestamp":1718125200,"startTime":"0","endTime":"0","summary":"Wall Street was upbeat last week. The S&P 500 added 1.3% last week, the Dow Jones inched up 0.3% last week and the Nasdaq Composite advanced 2.4% last week. Easing inflation, soft manufacturing data renewed Fed rate cut bets and the strengthening of the tech rally led to the gains last week.A decline in Treasury yields earlier in the week bolstered the market rally. Both the 10-year and 30-year rates reached their lowest levels since late March. U.S. technology stocks recorded their largest weekly inflows last week in nine weeks, with the sector seeing a revival after its mega-cap-led rally lost steam by the end of May, per strategists at BofA Global Research, as quoted on MarketWatch.Tech stocks hauled in nearly $1 billion in the week ending Wednesday, the highest in more than two months, after experiencing the same amount of outflows the previous week, a team of strategists led by Michael Hartnett, chief investment strategist at BofA Global Research, said in a Friday client note.Agai","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/HBog1YPW7NCCMwW6yxJvOQ--~B/aD02NzU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6b9a9b5efb2098eeeb3b090103acdd08","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/HBog1YPW7NCCMwW6yxJvOQ--~B/aD02NzU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6b9a9b5efb2098eeeb3b090103acdd08"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/best-etf-areas-last-week-170000862.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FDN","BK4507","UNG","IE00BKVL7J92.USD","LU0079474960.USD","IE0004445015.USD","LU0943347566.SGD","US30Y.BOND","US3Y.BOND","DAPP","LU0061474705.USD","US912797FS14.BOND","US912797GW17.BOND","LU0289960550.SGD","BK4573","IE0004445239.USD","LRNZ","LU1623119135.USD","US912797GL51.BOND","US912797HE00.BOND","BK4533","LLY","BK4501","NVDA","LU1267930730.SGD","BK4587","AAPL","US7Y.BOND","OZEM","US912797GB79.BOND","LU0053666078.USD","BK4585","IE00B1BXHZ80.USD","US10Y.BOND","BK4567","US12M.BOND","LU0820561909.HKD","LU0234570918.USD","SMH","WGMI","UNL","LU0289739699.SGD","US912797GK78.BOND","BK4551","BK4581","US5Y.BOND","US2Y.BOND","US6M.BOND","NVO","LU1064131342.USD"],"gpt_icon":0},{"id":"2441255948","title":"ETFs to Profit from the Weight Loss Drug Boom","url":"https://stock-news.laohu8.com/highlight/detail?id=2441255948","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2441255948?lang=en_us&edition=fundamental","pubTime":"2024-06-04 23:45","pubTimestamp":1717515900,"startTime":"0","endTime":"0","summary":"Two dominant investing themes over the past year have been AI and weight-loss drugs. While there's a lot of excitement around AI, particularly with NVIDIA NVDA, shares of two companies that dominate the weight-loss drug market have also surged over the past year due to soaring demand for their products.Shares of Eli Lilly LLY are up over 89% over the past year, and its market capitalization surpassed Tesla's TSLA earlier this year. Shares of Novo Nordisk are up over 73%, making it the biggest European firm by market value.More than 1 billion individuals worldwide are living with obesity, a figure expected to impact over half the population by 2035. Obesity is linked to numerous health risks, including diabetes, heart disease, stroke, and cancer.GLP-1 medications mimic the effects of the naturally occurring hormone glucagon-like peptide-1, which is produced in the intestine after eating. These drugs were initially used to treat diabetes but were later found to control blood sugar level","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/etfs-profit-weight-loss-drug-154500848.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0127658192.USD","LU0061474960.USD","LU1064131342.USD","LU0466842654.USD","LU1804176565.USD","IE00B3M56506.USD","BK4587","LU0943347566.SGD","FDN","IE00BJJMRZ35.SGD","LU0719512351.SGD","LU0058720904.USD","LU2249611893.SGD","IE0004445015.USD","BK4585","OZEM","IE0009356076.USD","LU1914381329.SGD","LU0820561909.HKD","LLY","LU1720051017.SGD","LU0456855351.SGD","LU0079474960.USD","LU0882574139.USD","LU1712237335.SGD","LU1720051108.HKD","IE0034235295.USD","BK4579","LU2264538146.SGD","LU2602419157.SGD","HRTS","IE00BJJMRY28.SGD","IE00BKVL7J92.USD","LU0114720955.EUR","LU0256863811.USD","LU1623119135.USD","LU1861558580.USD","LU2265009873.SGD","IE00BJJMRX11.SGD","LU1551013425.SGD","IE00B1XK9C88.USD","LU0289961442.SGD","LU0689472784.USD","LU0708995401.HKD","THNR","NVDA","LU0170899867.USD","NVO","LU0882574055.USD","IE00BDCRKT87.USD"],"gpt_icon":0},{"id":"2438168818","title":"Eli Lilly: Addressing Supply Challenges Should Accelerate Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2438168818","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2438168818?lang=en_us&edition=fundamental","pubTime":"2024-05-27 03:19","pubTimestamp":1716751179,"startTime":"0","endTime":"0","summary":"Eli Lilly's shares reached new all-time highs after the company increased full-year revenue and EPS guidance.The company's growth is currently supply-constrained and the growth of tirzepatide in the n","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/521503314/image_521503314.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/521503314/image_521503314.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4695745-eli-lilly-stock-lly-addressing-supply-challenges-should-accelerate-growth","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["LU0708995401.HKD","IE0004445239.USD","LU2264538146.SGD","SG9999001440.SGD","BK4533","BK4534","OZEM","VKTX","BK4532","LU1814569148.SGD","LU2491049909.HKD","LU0289739699.SGD","LU2237443382.USD","AMGN","LU0320765992.SGD","LU0882574055.USD","LU0058720904.USD","LU1804176565.USD","LU0109391861.USD","GB00BDT5M118.USD","LU2468319806.SGD","REGN","IE00BJT1NW94.SGD","LU2491050071.SGD","03165","LU0256863811.USD","LU1551013425.SGD","LU1988902786.USD","NVO","LU0211331839.USD","LLY","AAQC","IE00BJJMRZ35.SGD","LU0061475181.USD","LU0122379950.USD","LU2237438978.USD","LU0079474960.USD","LU1551013342.USD","BK4007","LU0053666078.USD","NVS","IE0002141913.USD","IE00B1BXHZ80.USD","LU1057294990.SGD","LU0868494617.USD","LU1571399168.USD","LU2491050154.USD","LU1023059063.AUD","LU1280957306.USD","RHHBY"],"gpt_icon":0},{"id":"2437942652","title":"Play These New ETFs to Tap Lucrative Weight Loss Drug Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2437942652","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2437942652?lang=en_us&edition=fundamental","pubTime":"2024-05-22 20:38","pubTimestamp":1716381480,"startTime":"0","endTime":"0","summary":"Global obesity rates have nearly tripled since 1975 and are expected to affect over half the population by 2035, per WHO and Goldman Sachs. Pioneering GLP-1 treatments, such as Ozempic, Wegovy, and Zepbound, are now at the forefront of medical advancements in weight management.GLP-1 medications, initially used to treat diabetes, were later discovered to suppress appetite and lead to considerable weight loss. Recent studies suggest that GLP-1 drugs may also slow the progression of Parkinson’s symptoms in humans and lower the risk of heart attack, stroke and cardiovascular death by approximately 20%.No wonder, investors are closely monitoring these developments. After all, over 42% of U.S. adults and 1 billion people worldwide are obese now. There is intense competition among the companies producing GLP-1 medicines, and the stocks of many of these firms have experienced significant surges in recent months.The 27-stock fund, which also made a recent entry, provides exposure to companies i","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/g.raN2f2Gj9gsgHh3Sjz.Q--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/g.raN2f2Gj9gsgHh3Sjz.Q--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/play-etfs-tap-lucrative-weight-123800304.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0097036916.USD","LU0122379950.USD","LU2491050154.USD","THNR","BK4550","LU0689472784.USD","IE0004445239.USD","LU1280957306.USD","LU2237443978.SGD","LU1668664300.SGD","LU1804176565.USD","LU0708995401.HKD","LLY","LU0106831901.USD","LU0882574055.USD","LU1551013342.USD","LU0943347566.SGD","LU1712237335.SGD","LU2237443382.USD","LU0058720904.USD","LU2237443549.SGD","IE00BJT1NW94.SGD","LU0114720955.EUR","LU2491049909.HKD","LU0820561818.USD","NVO","LU2265009873.SGD","LU2491050071.SGD","IE0009355771.USD","IE00B1BXHZ80.USD","IE00BJJMRZ35.SGD","LU0820561909.HKD","IE0002141913.USD","BK4552","LU1551013425.SGD","BK4585","BK4588","BK4007","LU2264538146.SGD","FDN","OZEM","LU0079474960.USD","GB00BDT5M118.USD","LU0882574139.USD","LU2237443622.USD","LU1623119135.USD","LU0256863811.USD","HRTS","IE0034235188.USD"],"gpt_icon":0},{"id":"2437785714","title":"Two US asset managers launch weight-loss ETFs","url":"https://stock-news.laohu8.com/highlight/detail?id=2437785714","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2437785714?lang=en_us&edition=fundamental","pubTime":"2024-05-22 04:21","pubTimestamp":1716322907,"startTime":"0","endTime":"0","summary":"By Suzanne McGee May 21 (Reuters) - Two separate asset-management firms announced the debut of exchange-traded funds (ETFs) on Tuesday, both which are designed to give investors exposure to stock","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0061475181.USD","LU0882574139.USD","IE00B1BXHZ80.USD","LU2237438978.USD","BK4585","LU2265009873.SGD","LU1988902786.USD","LU0820561909.HKD","BK4533","BK4550","LU0058720904.USD","LU1267930730.SGD","LU0466842654.USD","IE00BJT1NW94.SGD","LU1023059063.AUD","BK4534","BK4588","LU0109391861.USD","FDN","LU1712237335.SGD","LU0417517546.SGD","IE00BJJMRZ35.SGD","LU2602419157.SGD","LU0097036916.USD","LU1280957306.USD","LU1057294990.SGD","LU0708995401.HKD","LU0820561818.USD","LU0122379950.USD","LU0289739699.SGD","LU0198837287.USD","LU0640476718.USD","BK4581","LU0672654240.SGD","OZEM","LLY","LU0320765059.SGD","LU0456855351.SGD","LU2468319806.SGD","IE0004445239.USD","LU0238689110.USD","IE0009355771.USD","IE00B2B36J28.USD","LU1064131342.USD","LU1623119135.USD","LU1814569148.SGD","LU0689472784.USD","HRTS","IE00BFTCPJ56.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.roundhillinvestments.com/etf/ozem","stockEarnings":[{"period":"1week","weight":-0.0046},{"period":"1month","weight":-0.0154},{"period":"3month","weight":0.0865},{"period":"6month","weight":0.1087},{"period":"ytd","weight":0.1087}],"compareEarnings":[{"period":"1week","weight":0.0126},{"period":"1month","weight":0.0032},{"period":"3month","weight":0.0263},{"period":"6month","weight":0.0771},{"period":"1year","weight":0.2681},{"period":"ytd","weight":0.1811}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"Roundhill GLP-1 & Weight Loss ETF","nameEN":"Roundhill GLP-1 & Weight Loss ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.26.4","shortVersion":"4.26.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Roundhill GLP-1 & Weight Loss ETF(OZEM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Roundhill GLP-1 & Weight Loss ETF(OZEM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Roundhill GLP-1 & Weight Loss ETF,OZEM,Roundhill GLP-1 & Weight Loss ETF股票,Roundhill GLP-1 & Weight Loss ETF股票老虎,Roundhill GLP-1 & Weight Loss ETF股票老虎国际,Roundhill GLP-1 & Weight Loss ETF行情,Roundhill GLP-1 & Weight Loss ETF股票行情,Roundhill GLP-1 & Weight Loss ETF股价,Roundhill GLP-1 & Weight Loss ETF股市,Roundhill GLP-1 & Weight Loss ETF股票价格,Roundhill GLP-1 & Weight Loss ETF股票交易,Roundhill GLP-1 & Weight Loss ETF股票购买,Roundhill GLP-1 & Weight Loss ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Roundhill GLP-1 & Weight Loss ETF(OZEM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Roundhill GLP-1 & Weight Loss ETF(OZEM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}